[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100501852":3},{"organization":4,"armGroups":7,"interventions":49,"overallOfficials":54,"centralContacts":75,"locations":81,"responsibleParty":99,"collaborators":102,"id":109,"slug":110,"hasResults":111,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":111,"sex":117,"minAge":118,"maxAge":119,"enrollmentInfo":120,"targetDuration":54,"studyType":123,"phases":124,"briefSummary":127,"conditions":128,"keywords":54,"overallStatus":84,"whyStopped":54,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":140},{"fullName":5,"class":6},"First Affiliated Hospital of Chongqing Medical University","OTHER",[8,14,19,24,29,34,39,44],{"label":9,"type":10,"description":11,"interventionNames":12},"Fluoxetine","EXPERIMENTAL","Dosage form: po Dosage: 10-60mg Frequency: qn Course of treatment: 8 weeks. At week 8, patients will be evaluated as \"in \" or \"not in remission.\" \"Patients who are not in remission\" will be randomized to phase II treatment based on the patient's wishes.",[13],"Drug: Fluoxetine",{"label":15,"type":10,"description":16,"interventionNames":17},"group cognitive behavioral therapy（GCBT）","GCBT was administered in addition to fluoxetine and consisted of 11 sessions for 8 weeks. It lasts 90 to 120 minutes, once or twice a week. At week 8, patients will be evaluated as \"in remission\" or \"not in remission.\" \"Patients who are not in remission\" will be randomized to phase II treatment based on the patient's wishes.",[18],"Behavioral: GCBT",{"label":20,"type":10,"description":21,"interventionNames":22},"Sertraline","dosage form: po dosage:25-200mg frequency:qn duration: At Week 8, patients assessed as 'non-remission' will be given Sertraline as a switching treatment to fluoxetine.",[23],"Drug: Sertraline",{"label":25,"type":10,"description":26,"interventionNames":27},"Vortioxetine","dosage form: po dosage: 10-20mg frequency:qn duration: At Week 8, patients assessed as 'non-remission' will be given votioxetine as a switching treatment to fluoxetine.",[28],"Drug: Vortioxetine",{"label":30,"type":10,"description":31,"interventionNames":32},"Duloxetine","dosage form: po dosage: 60-120mg frequency: qn duration: At Week 8, patients assessed as 'non-remission' will be given duloxetine as an add-on treatment to fluoxetine.",[33],"Drug: Duloxetine",{"label":35,"type":10,"description":36,"interventionNames":37},"Aripiprazole","dosage form: po dosage: 2.5-15mg frequency:qn duration: At Week 8, patients assessed as 'non-remission' will be given aripiprazole as an add-on treatment to fluoxetine.",[38],"Drug: Aripiprazole",{"label":40,"type":10,"description":41,"interventionNames":42},"Lithium carbonate","dosage form: po dosage: 125-500mg frequency: qn duration: At Week 8, patients assessed as 'non-response' will be given lithium carbonate as an add-on treatment to fluoxetine.",[43],"Drug: Lithium Carbonate",{"label":45,"type":10,"description":46,"interventionNames":47},"Olanzapine","dosage form:po dosage: 1.25-10mg frequency:qn duration: At Week 8, patients assessed as 'non-rremission' will be given olanzapine as an add-on treatment to fluoxetine.",[48],"Drug: Olanzapine",[50,55,57,59,61,64,68,70],{"type":51,"name":9,"description":52,"armGroupLabels":53,"otherNames":54},"DRUG","Commonly used oral antidepressant.",[9],null,{"type":51,"name":20,"description":52,"armGroupLabels":56,"otherNames":54},[20],{"type":51,"name":25,"description":52,"armGroupLabels":58,"otherNames":54},[25],{"type":51,"name":30,"description":52,"armGroupLabels":60,"otherNames":54},[30],{"type":51,"name":35,"description":62,"armGroupLabels":63,"otherNames":54},"Commonly used oral augmentation therapy for antidepressants",[35],{"type":51,"name":65,"description":66,"armGroupLabels":67,"otherNames":54},"Lithium Carbonate","Commonly used oral augmentation therapy for antidepressants.",[40],{"type":51,"name":45,"description":66,"armGroupLabels":69,"otherNames":54},[45],{"type":71,"name":72,"description":73,"armGroupLabels":74,"otherNames":54},"BEHAVIORAL","GCBT","Commonly used intervention therapy of psychotherapy.",[15],[76],{"name":77,"role":78,"phone":79,"phoneExt":54,"email":80},"Xinyu Zhou","CONTACT","15823996993","zhouxinyu@cqmu.edu.cn",[82],{"facility":83,"status":84,"city":85,"state":86,"zip":87,"country":88,"countryCode":89,"cosmosGeoPoint":90,"geoPoint":95,"contacts":96},"The First Affiliated Hospital of Chongqing Medical University","RECRUITING","Chongqing","Province","400000","China","CN",{"type":91,"coordinates":92},"Point",[93,94],106.55771,29.56026,{"lat":94,"lon":93},[97],{"name":98,"role":78,"phone":79,"phoneExt":54,"email":80},"Zhou Xinyu, Doctor of Philosophy",{"type":100,"investigatorFullName":77,"investigatorTitle":101,"investigatorAffiliation":5,"oldNameTitle":54,"oldOrganization":54},"PRINCIPAL_INVESTIGATOR","professor",[103,105,107],{"name":104,"class":6},"The Second Affiliated Hospital of Chongqing Medical University",{"name":106,"class":6},"Second Xiangya Hospital of Central South University",{"name":108,"class":6},"Children's Hospital of Chongqing Medical University","100501852","phase-1-sequenced-treatment-alternatives-to-relieve-adolescent-depression-star-ad-100501852",false,"NCT05814640","Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)","Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD): a Pragmatic Clinical Trial","STAR-AD","Inclusion Criteria:\n\n1. Age 13 - 18\n2. As assessed by K-SADS-PL, it meets the DSM-V criteria for MDD with non-psychotic symptoms\n3. Score≥40 on the CDRS-R\n4. Participants with suicidal ideation are eligible, as long as clinicians consider outpatient treatment to be safe\n5. Sufficient audio-visual level to complete this study\n6. Written informed consent was obtained from patients and at least one of their parents\n\nExclusion Criteria:\n\n1. History of bipolar disorder, schizophrenia, autism, eating disorders, primary obsessive compulsive disorder, pervasive developmental disorder, or psychosis not otherwise specified\n2. History of serious physical illnesses\n3. Substance abuse or dependence\n4. Current depressive episode with clear suicidal plans or suicidal behavior\n5. Requires inpatient treatment for psychiatric disorders\n6. Severe mental disorders requiring\n7. 2 or more failed trials of antidepressant drugs: each trial for at least 8 weeks, with the last 4 weeks at full dose (e.g. fluoxetine 40mg\u002Fd, citalopram 40mg\u002Fd, escitalopram 20mg\u002Fd, sertraline 150mg\u002Fd )\n8. History of clear-cut intolerability of, or lack of effect with, an adequate trial of at least one protocol treatment option\n9. Taking any medicine that contraindicates in combination with or interferes with the efficacy of the treatment\n10. Taking or administering antidepressants within 5 half-lives\n11. Received modified electroconvulsive therapy within 12 months\n12. If female, is pregnant","ALL","13 Years","18 Years",{"count":121,"type":122},520,"ESTIMATED","INTERVENTIONAL",[125,126],"PHASE1","PHASE2","This project aims to investigate the effectiveness of existing common antidepressants and to provide new evidence for depressed children and adolescents who are not responding to their first treatment.",[129,130],"Depression","Sequestra","2026-01-25",{"date":133,"type":134},"2026-01-27","ACTUAL",{"date":136,"type":134},"2023-02-20",{"date":138,"type":122},"2027-07-01",{"name":5,"class":6},1]